Troponin T and neurofilament light chain captured different aspects of ALS progression
Original source
Troponin T and Neurofilament Light Chain Levels as Complementary Biomarkers of Disease Accumulation and Aggressiveness in Amyotrophic Lateral Sclerosis. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Studied in
- Human
Population inferred from the title and abstract by Compass.
Related topics
A retrospective study found that troponin T was associated with disease accumulation in people with amyotrophic lateral sclerosis (ALS), while serum neurofilament light chain was more closely associated with disease aggressiveness. The findings were based on two German cohorts, with 433 people in the discovery cohort and 185 in the replication cohort. Further longitudinal research is needed before combined use can be assessed in clinical care or trials.
Why this matters
The results suggest these blood-based biomarkers may provide different information about ALS disease status. This could eventually help researchers stratify participants or assess prognosis, but the study does not show that testing either biomarker improves treatment or outcomes.
Limitations and context
This was a retrospective observational study. Some subgroup findings for troponin T were not replicated, and the authors say longitudinal studies are still needed to test whether combining the biomarkers improves stratification or prognostic assessment.